



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ramucirumab (anti-VEGFR)

Cat. No.:	HY-P9920A
CAS No.:	947687-13-0
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor ^{[1][2]} .
In Vitro	Ramucirumab (10 µg/mL) impedes both VEGF- and tumor-driven cord formation ^[3] . ?Ramucirumab does not cross react with mouse VEGFR2 ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.
- [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.
- [3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA